Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease
Introduction ALZ-801/valiltramiprosate is a small-molecule oral inhibitor of beta amyloid (Aβ) aggregation and oligomer formation being studied in a phase 2 trial in APOE4 carriers with early Alzheimer’s disease (AD) to evaluate treatment effects on fluid and imaging biomarkers and cognitive assessm...
Saved in:
| Published in | Drugs (New York, N.Y.) Vol. 84; no. 7; pp. 811 - 823 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cham
Springer International Publishing
01.07.2024
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0012-6667 1179-1950 1179-1950 |
| DOI | 10.1007/s40265-024-02067-8 |
Cover
| Abstract | Introduction
ALZ-801/valiltramiprosate is a small-molecule oral inhibitor of beta amyloid (Aβ) aggregation and oligomer formation being studied in a phase 2 trial in APOE4 carriers with early Alzheimer’s disease (AD) to evaluate treatment effects on fluid and imaging biomarkers and cognitive assessments.
Methods
The single-arm, open-label phase 2 trial was designed to evaluate the effects of the ALZ-801 265 mg tablet taken twice daily (after 2 weeks once daily) on plasma fluid AD biomarkers, hippocampal volume (HV), and cognition over 104 weeks in APOE4 carriers. The study enrolled subjects aged 50–80 years, with early AD [Mini-Mental State Examination (MMSE) ≥ 22, Clinical Dementia Rating-Global (CDR-G) 0.5 or 1], apolipoprotein E4 (APOE4) genotypes including APOE4/4 and APOE3/4 genotypes, and positive cerebrospinal fluid (CSF) AD biomarkers or prior amyloid scans. The primary outcome was plasma p-tau
181
, HV evaluated by magnetic resonance imaging (MRI) was the key secondary outcome, and plasma Aβ42 and Aβ40 were the secondary biomarker outcomes. The cognitive outcomes were the Rey Auditory Verbal Learning Test and the Digit Symbol Substitution Test. Safety and tolerability evaluations included treatment-emergent adverse events and amyloid-related imaging abnormalities (ARIA). The study was designed and powered to detect 15% reduction from baseline in plasma p-tau
181
at the 104-week endpoint. A sample size of 80 subjects provided adequate power to detect this difference at a significance level of 0.05 using a two-sided paired
t
-test.
Results
The enrolled population of 84 subjects (31 homozygotes and 53 heterozygotes) was 52% females, mean age 69 years, MMSE 25.7 [70% mild cognitive impairment (MCI), 30% mild AD] with 55% on cholinesterase inhibitors. Plasma p-tau
181
reduction from baseline was significant (31%,
p
= 0.045) at 104 weeks and all prior visits; HV atrophy was significantly reduced (
p
= 0.0014) compared with matched external controls from an observational Early AD study. Memory scores showed minimal decline from baseline over 104 weeks and correlated significantly with decreased HV atrophy (Spearman’s 0.44,
p
= 0.002). Common adverse events were COVID infection and mild nausea, and no drug-related serious adverse events were reported. Of 14 early terminations, 6 were due to nonserious treatment-emergent adverse events and 1 death due to COVID. There was no vasogenic brain edema observed on MRI over 104 weeks.
Conclusions
The effect of ALZ-801 on reducing plasma p-tau
181
over 2 years demonstrates target engagement and supports its anti-Aβ oligomer action that leads to a robust decrease in amyloid-induced brain neurodegeneration. The significant correlation between reduced HV atrophy and cognitive stability over 2 years suggests a disease-modifying effect of ALZ-801 treatment in patients with early AD. Together with the favorable safety profile with no events of vasogenic brain edema, these results support further evaluation of ALZ-801 in a broader population of APOE4 carriers, who represent two-thirds of patients with AD.
Trial Registration
https://clinicaltrials.gov/study/NCT04693520
. |
|---|---|
| AbstractList | Introduction
ALZ-801/valiltramiprosate is a small-molecule oral inhibitor of beta amyloid (Aβ) aggregation and oligomer formation being studied in a phase 2 trial in APOE4 carriers with early Alzheimer’s disease (AD) to evaluate treatment effects on fluid and imaging biomarkers and cognitive assessments.
Methods
The single-arm, open-label phase 2 trial was designed to evaluate the effects of the ALZ-801 265 mg tablet taken twice daily (after 2 weeks once daily) on plasma fluid AD biomarkers, hippocampal volume (HV), and cognition over 104 weeks in APOE4 carriers. The study enrolled subjects aged 50–80 years, with early AD [Mini-Mental State Examination (MMSE) ≥ 22, Clinical Dementia Rating-Global (CDR-G) 0.5 or 1], apolipoprotein E4 (APOE4) genotypes including APOE4/4 and APOE3/4 genotypes, and positive cerebrospinal fluid (CSF) AD biomarkers or prior amyloid scans. The primary outcome was plasma p-tau
181
, HV evaluated by magnetic resonance imaging (MRI) was the key secondary outcome, and plasma Aβ42 and Aβ40 were the secondary biomarker outcomes. The cognitive outcomes were the Rey Auditory Verbal Learning Test and the Digit Symbol Substitution Test. Safety and tolerability evaluations included treatment-emergent adverse events and amyloid-related imaging abnormalities (ARIA). The study was designed and powered to detect 15% reduction from baseline in plasma p-tau
181
at the 104-week endpoint. A sample size of 80 subjects provided adequate power to detect this difference at a significance level of 0.05 using a two-sided paired
t
-test.
Results
The enrolled population of 84 subjects (31 homozygotes and 53 heterozygotes) was 52% females, mean age 69 years, MMSE 25.7 [70% mild cognitive impairment (MCI), 30% mild AD] with 55% on cholinesterase inhibitors. Plasma p-tau
181
reduction from baseline was significant (31%,
p
= 0.045) at 104 weeks and all prior visits; HV atrophy was significantly reduced (
p
= 0.0014) compared with matched external controls from an observational Early AD study. Memory scores showed minimal decline from baseline over 104 weeks and correlated significantly with decreased HV atrophy (Spearman’s 0.44,
p
= 0.002). Common adverse events were COVID infection and mild nausea, and no drug-related serious adverse events were reported. Of 14 early terminations, 6 were due to nonserious treatment-emergent adverse events and 1 death due to COVID. There was no vasogenic brain edema observed on MRI over 104 weeks.
Conclusions
The effect of ALZ-801 on reducing plasma p-tau
181
over 2 years demonstrates target engagement and supports its anti-Aβ oligomer action that leads to a robust decrease in amyloid-induced brain neurodegeneration. The significant correlation between reduced HV atrophy and cognitive stability over 2 years suggests a disease-modifying effect of ALZ-801 treatment in patients with early AD. Together with the favorable safety profile with no events of vasogenic brain edema, these results support further evaluation of ALZ-801 in a broader population of APOE4 carriers, who represent two-thirds of patients with AD.
Trial Registration
https://clinicaltrials.gov/study/NCT04693520
. ALZ-801/valiltramiprosate is a small-molecule oral inhibitor of beta amyloid (Aβ) aggregation and oligomer formation being studied in a phase 2 trial in APOE4 carriers with early Alzheimer's disease (AD) to evaluate treatment effects on fluid and imaging biomarkers and cognitive assessments. The single-arm, open-label phase 2 trial was designed to evaluate the effects of the ALZ-801 265 mg tablet taken twice daily (after 2 weeks once daily) on plasma fluid AD biomarkers, hippocampal volume (HV), and cognition over 104 weeks in APOE4 carriers. The study enrolled subjects aged 50-80 years, with early AD [Mini-Mental State Examination (MMSE) ≥ 22, Clinical Dementia Rating-Global (CDR-G) 0.5 or 1], apolipoprotein E4 (APOE4) genotypes including APOE4/4 and APOE3/4 genotypes, and positive cerebrospinal fluid (CSF) AD biomarkers or prior amyloid scans. The primary outcome was plasma p-tau , HV evaluated by magnetic resonance imaging (MRI) was the key secondary outcome, and plasma Aβ42 and Aβ40 were the secondary biomarker outcomes. The cognitive outcomes were the Rey Auditory Verbal Learning Test and the Digit Symbol Substitution Test. Safety and tolerability evaluations included treatment-emergent adverse events and amyloid-related imaging abnormalities (ARIA). The study was designed and powered to detect 15% reduction from baseline in plasma p-tau at the 104-week endpoint. A sample size of 80 subjects provided adequate power to detect this difference at a significance level of 0.05 using a two-sided paired t-test. The enrolled population of 84 subjects (31 homozygotes and 53 heterozygotes) was 52% females, mean age 69 years, MMSE 25.7 [70% mild cognitive impairment (MCI), 30% mild AD] with 55% on cholinesterase inhibitors. Plasma p-tau reduction from baseline was significant (31%, p = 0.045) at 104 weeks and all prior visits; HV atrophy was significantly reduced (p = 0.0014) compared with matched external controls from an observational Early AD study. Memory scores showed minimal decline from baseline over 104 weeks and correlated significantly with decreased HV atrophy (Spearman's 0.44, p = 0.002). Common adverse events were COVID infection and mild nausea, and no drug-related serious adverse events were reported. Of 14 early terminations, 6 were due to nonserious treatment-emergent adverse events and 1 death due to COVID. There was no vasogenic brain edema observed on MRI over 104 weeks. The effect of ALZ-801 on reducing plasma p-tau over 2 years demonstrates target engagement and supports its anti-Aβ oligomer action that leads to a robust decrease in amyloid-induced brain neurodegeneration. The significant correlation between reduced HV atrophy and cognitive stability over 2 years suggests a disease-modifying effect of ALZ-801 treatment in patients with early AD. Together with the favorable safety profile with no events of vasogenic brain edema, these results support further evaluation of ALZ-801 in a broader population of APOE4 carriers, who represent two-thirds of patients with AD. https://clinicaltrials.gov/study/NCT04693520 . Introduction ALZ-801/valiltramiprosate is a small-molecule oral inhibitor of beta amyloid (A beta) aggregation and oligomer formation being studied in a phase 2 trial in APOE4 carriers with early Alzheimer's disease (AD) to evaluate treatment effects on fluid and imaging biomarkers and cognitive assessments.Methods The single-arm, open-label phase 2 trial was designed to evaluate the effects of the ALZ-801 265 mg tablet taken twice daily (after 2 weeks once daily) on plasma fluid AD biomarkers, hippocampal volume (HV), and cognition over 104 weeks in APOE4 carriers. The study enrolled subjects aged 50-80 years, with early AD [Mini-Mental State Examination (MMSE) >= 22, Clinical Dementia Rating-Global (CDR-G) 0.5 or 1], apolipoprotein E4 (APOE4) genotypes including APOE4/4 and APOE3/4 genotypes, and positive cerebrospinal fluid (CSF) AD biomarkers or prior amyloid scans. The primary outcome was plasma p-tau181, HV evaluated by magnetic resonance imaging (MRI) was the key secondary outcome, and plasma A beta 42 and A beta 40 were the secondary biomarker outcomes. The cognitive outcomes were the Rey Auditory Verbal Learning Test and the Digit Symbol Substitution Test. Safety and tolerability evaluations included treatment-emergent adverse events and amyloid-related imaging abnormalities (ARIA). The study was designed and powered to detect 15% reduction from baseline in plasma p-tau181 at the 104-week endpoint. A sample size of 80 subjects provided adequate power to detect this difference at a significance level of 0.05 using a two-sided paired t-test.Results The enrolled population of 84 subjects (31 homozygotes and 53 heterozygotes) was 52% females, mean age 69 years, MMSE 25.7 [70% mild cognitive impairment (MCI), 30% mild AD] with 55% on cholinesterase inhibitors. Plasma p-tau181 reduction from baseline was significant (31%, p = 0.045) at 104 weeks and all prior visits; HV atrophy was significantly reduced (p = 0.0014) compared with matched external controls from an observational Early AD study. Memory scores showed minimal decline from baseline over 104 weeks and correlated significantly with decreased HV atrophy (Spearman's 0.44, p = 0.002). Common adverse events were COVID infection and mild nausea, and no drug-related serious adverse events were reported. Of 14 early terminations, 6 were due to nonserious treatment-emergent adverse events and 1 death due to COVID. There was no vasogenic brain edema observed on MRI over 104 weeks.Conclusions The effect of ALZ-801 on reducing plasma p-tau181 over 2 years demonstrates target engagement and supports its anti-A beta oligomer action that leads to a robust decrease in amyloid-induced brain neurodegeneration. The significant correlation between reduced HV atrophy and cognitive stability over 2 years suggests a disease-modifying effect of ALZ-801 treatment in patients with early AD. Together with the favorable safety profile with no events of vasogenic brain edema, these results support further evaluation of ALZ-801 in a broader population of APOE4 carriers, who represent two-thirds of patients with AD.Trial Registration https://clinicaltrials.gov/study/NCT04693520. Introduction ALZ-801/valiltramiprosate is a small-molecule oral inhibitor of beta amyloid (Aβ) aggregation and oligomer formation being studied in a phase 2 trial in APOE4 carriers with early Alzheimer's disease (AD) to evaluate treatment effects on fluid and imaging biomarkers and cognitive assessments. Methods The single-arm, open-label phase 2 trial was designed to evaluate the effects of the ALZ-801 265 mg tablet taken twice daily (after 2 weeks once daily) on plasma fluid AD biomarkers, hippocampal volume (HV), and cognition over 104 weeks in APOE4 carriers. The study enrolled subjects aged 50–80 years, with early AD [Mini-Mental State Examination (MMSE)≥22, Clinical Dementia Rating-Global (CDR-G) 0.5 or 1], apolipoprotein E4 (APOE4) genotypes including APOE4/4 and APOE3/4 genotypes, and positive cerebrospinal fluid (CSF) AD biomarkers or prior amyloid scans. The primary outcome was plasma p-tau181, HV evaluated by magnetic resonance imaging (MRI) was the key secondary outcome, and plasma Aβ42 and Aβ40 were the secondary biomarker outcomes. The cognitive outcomes were the Rey Auditory Verbal Learning Test and the Digit Symbol Substitution Test. Safety and tolerability evaluations included treatment-emergent adverse events and amyloid-related imaging abnormalities (ARIA). The study was designed and powered to detect 15% reduction from baseline in plasma p-tau181 at the 104-week endpoint. A sample size of 80 subjects provided adequate power to detect this difference at a significance level of 0.05 using a two-sided paired t-test. Results The enrolled population of 84 subjects (31 homozygotes and 53 heterozygotes) was 52% females, mean age 69 years, MMSE 25.7 [70% mild cognitive impairment (MCI), 30% mild AD] with 55% on cholinesterase inhibitors. Plasma p-tau181 reduction from baseline was significant (31%, p=0.045) at 104 weeks and all prior visits; HV atrophy was significantly reduced (p=0.0014) compared with matched external controls from an observational Early AD study. Memory scores showed minimal decline from baseline over 104 weeks and correlated significantly with decreased HV atrophy (Spearman's 0.44, p=0.002). Common adverse events were COVID infection and mild nausea, and no drug-related serious adverse events were reported. Of 14 early terminations, 6 were due to nonserious treatment-emergent adverse events and 1 death due to COVID. There was no vasogenic brain edema observed on MRI over 104 weeks. Conclusions The effect of ALZ-801 on reducing plasma p-tau181 over 2 years demonstrates target engagement and supports its anti-Aβ oligomer action that leads to a robust decrease in amyloid-induced brain neurodegeneration. The significant correlation between reduced HV atrophy and cognitive stability over 2 years suggests a disease-modifying effect of ALZ-801 treatment in patients with early AD. Together with the favorable safety profile with no events of vasogenic brain edema, these results support further evaluation of ALZ-801 in a broader population of APOE4 carriers, who represent two-thirds of patients with AD. ALZ-801/valiltramiprosate is a small-molecule oral inhibitor of beta amyloid (Aβ) aggregation and oligomer formation being studied in a phase 2 trial in APOE4 carriers with early Alzheimer's disease (AD) to evaluate treatment effects on fluid and imaging biomarkers and cognitive assessments.INTRODUCTIONALZ-801/valiltramiprosate is a small-molecule oral inhibitor of beta amyloid (Aβ) aggregation and oligomer formation being studied in a phase 2 trial in APOE4 carriers with early Alzheimer's disease (AD) to evaluate treatment effects on fluid and imaging biomarkers and cognitive assessments.The single-arm, open-label phase 2 trial was designed to evaluate the effects of the ALZ-801 265 mg tablet taken twice daily (after 2 weeks once daily) on plasma fluid AD biomarkers, hippocampal volume (HV), and cognition over 104 weeks in APOE4 carriers. The study enrolled subjects aged 50-80 years, with early AD [Mini-Mental State Examination (MMSE) ≥ 22, Clinical Dementia Rating-Global (CDR-G) 0.5 or 1], apolipoprotein E4 (APOE4) genotypes including APOE4/4 and APOE3/4 genotypes, and positive cerebrospinal fluid (CSF) AD biomarkers or prior amyloid scans. The primary outcome was plasma p-tau181, HV evaluated by magnetic resonance imaging (MRI) was the key secondary outcome, and plasma Aβ42 and Aβ40 were the secondary biomarker outcomes. The cognitive outcomes were the Rey Auditory Verbal Learning Test and the Digit Symbol Substitution Test. Safety and tolerability evaluations included treatment-emergent adverse events and amyloid-related imaging abnormalities (ARIA). The study was designed and powered to detect 15% reduction from baseline in plasma p-tau181 at the 104-week endpoint. A sample size of 80 subjects provided adequate power to detect this difference at a significance level of 0.05 using a two-sided paired t-test.METHODSThe single-arm, open-label phase 2 trial was designed to evaluate the effects of the ALZ-801 265 mg tablet taken twice daily (after 2 weeks once daily) on plasma fluid AD biomarkers, hippocampal volume (HV), and cognition over 104 weeks in APOE4 carriers. The study enrolled subjects aged 50-80 years, with early AD [Mini-Mental State Examination (MMSE) ≥ 22, Clinical Dementia Rating-Global (CDR-G) 0.5 or 1], apolipoprotein E4 (APOE4) genotypes including APOE4/4 and APOE3/4 genotypes, and positive cerebrospinal fluid (CSF) AD biomarkers or prior amyloid scans. The primary outcome was plasma p-tau181, HV evaluated by magnetic resonance imaging (MRI) was the key secondary outcome, and plasma Aβ42 and Aβ40 were the secondary biomarker outcomes. The cognitive outcomes were the Rey Auditory Verbal Learning Test and the Digit Symbol Substitution Test. Safety and tolerability evaluations included treatment-emergent adverse events and amyloid-related imaging abnormalities (ARIA). The study was designed and powered to detect 15% reduction from baseline in plasma p-tau181 at the 104-week endpoint. A sample size of 80 subjects provided adequate power to detect this difference at a significance level of 0.05 using a two-sided paired t-test.The enrolled population of 84 subjects (31 homozygotes and 53 heterozygotes) was 52% females, mean age 69 years, MMSE 25.7 [70% mild cognitive impairment (MCI), 30% mild AD] with 55% on cholinesterase inhibitors. Plasma p-tau181 reduction from baseline was significant (31%, p = 0.045) at 104 weeks and all prior visits; HV atrophy was significantly reduced (p = 0.0014) compared with matched external controls from an observational Early AD study. Memory scores showed minimal decline from baseline over 104 weeks and correlated significantly with decreased HV atrophy (Spearman's 0.44, p = 0.002). Common adverse events were COVID infection and mild nausea, and no drug-related serious adverse events were reported. Of 14 early terminations, 6 were due to nonserious treatment-emergent adverse events and 1 death due to COVID. There was no vasogenic brain edema observed on MRI over 104 weeks.RESULTSThe enrolled population of 84 subjects (31 homozygotes and 53 heterozygotes) was 52% females, mean age 69 years, MMSE 25.7 [70% mild cognitive impairment (MCI), 30% mild AD] with 55% on cholinesterase inhibitors. Plasma p-tau181 reduction from baseline was significant (31%, p = 0.045) at 104 weeks and all prior visits; HV atrophy was significantly reduced (p = 0.0014) compared with matched external controls from an observational Early AD study. Memory scores showed minimal decline from baseline over 104 weeks and correlated significantly with decreased HV atrophy (Spearman's 0.44, p = 0.002). Common adverse events were COVID infection and mild nausea, and no drug-related serious adverse events were reported. Of 14 early terminations, 6 were due to nonserious treatment-emergent adverse events and 1 death due to COVID. There was no vasogenic brain edema observed on MRI over 104 weeks.The effect of ALZ-801 on reducing plasma p-tau181 over 2 years demonstrates target engagement and supports its anti-Aβ oligomer action that leads to a robust decrease in amyloid-induced brain neurodegeneration. The significant correlation between reduced HV atrophy and cognitive stability over 2 years suggests a disease-modifying effect of ALZ-801 treatment in patients with early AD. Together with the favorable safety profile with no events of vasogenic brain edema, these results support further evaluation of ALZ-801 in a broader population of APOE4 carriers, who represent two-thirds of patients with AD.CONCLUSIONSThe effect of ALZ-801 on reducing plasma p-tau181 over 2 years demonstrates target engagement and supports its anti-Aβ oligomer action that leads to a robust decrease in amyloid-induced brain neurodegeneration. The significant correlation between reduced HV atrophy and cognitive stability over 2 years suggests a disease-modifying effect of ALZ-801 treatment in patients with early AD. Together with the favorable safety profile with no events of vasogenic brain edema, these results support further evaluation of ALZ-801 in a broader population of APOE4 carriers, who represent two-thirds of patients with AD.https://clinicaltrials.gov/study/NCT04693520 .TRIAL REGISTRATIONhttps://clinicaltrials.gov/study/NCT04693520 . |
| Author | Hey, John A. Prins, Niels D. Paul, Jijo Sheardova, Katerina Tolar, Martin Zhu, Xinyi Abushakra, Susan Shen, Larry Reiman, Eric M. Blennow, Kaj Power, Aidan Schaefer, Jean F. Hort, Jakub Kesslak, Patrick Albayrak, Adem |
| Author_xml | – sequence: 1 givenname: John A. orcidid: 0000-0002-5104-6231 surname: Hey fullname: Hey, John A. email: John.Hey@Alzheon.com organization: Alzheon, Inc – sequence: 2 givenname: Susan surname: Abushakra fullname: Abushakra, Susan organization: Alzheon, Inc – sequence: 3 givenname: Kaj surname: Blennow fullname: Blennow, Kaj organization: Neurochemical Pathology and Diagnostics Research Group, Department of Neuroscience and Physiology, University of Gothenburg – sequence: 4 givenname: Eric M. surname: Reiman fullname: Reiman, Eric M. organization: Banner Alzheimer’s Institute and University of Arizona – sequence: 5 givenname: Jakub surname: Hort fullname: Hort, Jakub organization: Memory Clinic, Department of Neurology, Second Faculty of Medicine and Motol University Hospital, Charles University – sequence: 6 givenname: Niels D. surname: Prins fullname: Prins, Niels D. organization: Brain Research Center – sequence: 7 givenname: Katerina surname: Sheardova fullname: Sheardova, Katerina organization: International Clinical Research Center, St. Anne’s University Hospital – sequence: 8 givenname: Patrick surname: Kesslak fullname: Kesslak, Patrick organization: Alzheon, Inc – sequence: 9 givenname: Larry surname: Shen fullname: Shen, Larry organization: Pharmapace Biometrics Solutions, a Unit of Wuxi AppTec – sequence: 10 givenname: Xinyi surname: Zhu fullname: Zhu, Xinyi organization: Pharmapace Biometrics Solutions, a Unit of Wuxi AppTec – sequence: 11 givenname: Adem surname: Albayrak fullname: Albayrak, Adem organization: Alzheon, Inc – sequence: 12 givenname: Jijo surname: Paul fullname: Paul, Jijo organization: Alzheon, Inc – sequence: 13 givenname: Jean F. surname: Schaefer fullname: Schaefer, Jean F. organization: Alzheon, Inc – sequence: 14 givenname: Aidan surname: Power fullname: Power, Aidan organization: Alzheon, Inc – sequence: 15 givenname: Martin surname: Tolar fullname: Tolar, Martin organization: Alzheon, Inc |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38902571$$D View this record in MEDLINE/PubMed https://gup.ub.gu.se/publication/339593$$DView record from Swedish Publication Index |
| BookMark | eNp9ks1u1DAUhSNURH_gBVggS2xYjKl_8uOwQdNhoEgjzQhKJdhYTuZmxsWxg51QlRWvwXPxBjwJHmYKtIsurMjJd869OjmHyZ51FpLkMSXPKSHFcUgJyzNMWBoPyQss7iUHlBYlpmVG9pIDQijDeZ4X-8lhCBeba5mVD5J9LkrCsoIeJD-nTQN1H5Br0Nwrg8azT1gQenyujDa9V63uvAuqB-QsWhgVWoVOtGuV_ww-jNCJV9qiU911rlZtFx3OnRlaGCFll2jiVlb32tkX6B2EwWwHMfwRlEfvtV0ZwGPfjtC8A4tnqgIzQou1CoAYOvM62kX38WI-TdFEea_jTHSp-zWaKm-u0Nh8W4Nuwf_6_iOgVzpAlD5M7jfKBHi0ex4lH15PzyaneDZ_83YynuE6o7zHhaKkWALUqm7IkkFaKchZKhhrhCApByBVBpWqq5IRnpU1y0jeiKKmrIlBMn6U4K1vuIRuqGTndYzlSjql5WroZHy1GmQAyXmMnUf-5ZaPcAvLGmzM19yQ3fxi9Vqu3FdJKRMlLTYOz3YO3n0ZIPSy1aEGY5QFNwTJSUEELzlLI_r0FnrhBm9jHpEqKRWsyGmknvy_0t9drgsSAbEF6tiC4KGRte7V5o_GDbWRlMhNF-W2izJ2Uf7pohRRym5Jr93vFPFdphG2K_D_1r5D9RtvIfL6 |
| CitedBy_id | crossref_primary_10_1007_s40262_025_01482_8 crossref_primary_10_1109_ACCESS_2024_3426085 crossref_primary_10_1016_j_tjpad_2024_100022 crossref_primary_10_1016_j_medj_2024_08_004 crossref_primary_10_1007_s40265_024_02068_7 |
| Cites_doi | 10.1002/alz.13455 10.1007/s40262-017-0608-3 10.1002/alz.13539 10.1038/s41591-024-02931-w 10.1016/0022-3956(75)90026-6 10.3389/fneur.2022.862369 10.1001/jamaneurol.2022.4485 10.1007/s40263-018-0554-0 10.1126/sciadv.aaz2387 10.1016/j.neurobiolaging.2012.04.017 10.1016/s1474-4422(20)30071-5 10.1038/nrneurol.2015.119 10.1212/WNL.0b013e3181cb3e25 10.1093/brain/awad188 10.3390/ijms25052727 10.1001/archneur.65.8.1091 10.1002/trc2.12117 10.1016/j.jalz.2011.05.2351 10.1016/j.jalz.2011.03.005 10.1212/WNL.000000000020355 10.1021/acs.jctc.9b00599 10.1523/JNEUROSCI.1542-12.2012 10.1056/NEJMoa2212948 10.1007/s40263-017-0434-z 10.1212/01.wnl.0000172913.88973.0d 10.1038/s41582-019-0281-2 10.1186/s13195-020-00663-w 10.1016/j.jalz.2008.10.004 10.1212/WNL.0000000000011270 10.1146/annurev.med.47.1.387 10.1001/jamaneurol.2021.5216 10.1093/geronj/33.2.232 10.1126/science.8346443 10.1016/j.jalz.2018.01.010 10.14283/jpad.2016.115 10.1136/jnnp-2013-306485 10.1001/jamaneurol.2020.4986 10.3390/ijms22126355 10.1001/jama.2015.4669 10.14283/jpad.2017.26 10.1016/j.jalz.2018.02.018 10.1186/1742-2094-1-24 10.14283/jpad.2023.30 10.14283/jpad.2022.21 10.1016/j.jalz.2011.03.008 10.1038/s41591-021-01382-x 10.1007/s40265-024-02068-7 10.14283/jpad.2023.68 10.14283/jpad.2022.30 10.1016/j.neurobiolaging.2023.04.003 10.1001/jama.2023.13239 10.1159/000334607 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). Copyright Springer Nature B.V. Jul 2024 The Author(s) 2024 2024 |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: Copyright Springer Nature B.V. Jul 2024 – notice: The Author(s) 2024 2024 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 4T- 7QO 7RV 7TK 7U7 7U9 7X7 7XB 88E 8FD 8FI 8FJ 8FK ABUWG AFKRA AN0 BENPR C1K CCPQU FR3 FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM ADTPV AOWAS F1U |
| DOI | 10.1007/s40265-024-02067-8 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Docstoc Biotechnology Research Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Index ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Proquest Medical Database Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) SwePub SwePub Articles SWEPUB Göteborgs universitet |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts Toxicology Abstracts ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Docstoc ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Technology Research Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: SpringerOpen Free (Free internet resource, activated by CARLI) url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1179-1950 |
| EndPage | 823 |
| ExternalDocumentID | oai_gup_ub_gu_se_339593 PMC11289173 38902571 10_1007_s40265_024_02067_8 |
| Genre | Clinical Trial, Phase II Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GroupedDBID | --- -5G -BR -EM .55 .GJ .XZ 04C 0R~ 0VX 29G 2JY 34G 36B 39C 3O- 3V. 4.4 406 53G 5GY 5RE 6I2 6PF 7RV 7X7 88E 8FI 8FJ 8R4 8R5 95. AAAUJ AABHQ AACDK AADNT AAIAL AAIKX AAJKR AAKAS AASML AATNV AAWTL AAYQN AAYTO AAYZH ABAKF ABCQX ABDZT ABFTV ABIPD ABJNI ABJOX ABKCH ABKMS ABKTR ABPLI ABTKH ABTMW ABUWG ABUWZ ABWHX ABXPI ACAOD ACCOQ ACCUX ACDTI ACGFS ACHVE ACIWK ACMLO ACPIV ACPRK ACZOJ ADBBV ADFZG ADHHG ADINQ ADKPE ADQRH ADRFC ADURQ ADZCM ADZKW AEBJR AEBTG AEFQL AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AEYRQ AFALF AFBBN AFFNX AFJLC AFKRA AFRAH AFWTZ AFZKB AGAYW AGDGC AGQEE AGQMX AGRTI AHBYD AHIZS AHMBA AHSBF AIAKS AIGIU AILAN AIZAD ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF AN0 ASPBG AUKKA AVWKF AWSVR AXYYD AZFZN A~4 BENPR BGNMA BKEYQ BNQBC BPHCQ BVXVI BYPQX C6C CAG CCPQU COF CS3 DCUDU DPUIP DU5 EBLON EBS ECV EIHBH EJD ESX EX3 F5P FIGPU FLLZZ FNLPD FSGXE FYUFA HF~ HMCUK IAO IEA IHR IMOTQ INH INR ITC IWAJR J-C JZLTJ L7B LLZTM M1P M4Y N4W NAPCQ NQJWS NU0 OAC OPC OVD P2P PCD PQQKQ PROAC PSQYO Q2X RKO ROL RSV RXW RZALA SISQX SJN SJYHP SNPRN SOHCF SOJ SPKJE SRMVM SSLCW TEORI TSG U9L UG4 UKHRP UTJUX VDBLX VFIZW W48 WAF WOW WQ9 X7M Y6R YFH Z0Y Z7U ZGI ZXP ~JE AAYXX ABBRH ABDBE ABFSG ACSTC AEZWR AFDZB AFHIU AFOHR AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 4T- 7QO 7TK 7U7 7U9 7XB 8FD 8FK ABRTQ C1K FR3 H94 K9. P64 PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 PUEGO 5PM ADTPV AOWAS F1U |
| ID | FETCH-LOGICAL-c513t-7a107deecacf0d2e4bae624822f88043ee0b5ebacb920359c2506f87c12f12923 |
| IEDL.DBID | C6C |
| ISSN | 0012-6667 1179-1950 |
| IngestDate | Tue Sep 09 23:12:25 EDT 2025 Thu Aug 21 18:33:49 EDT 2025 Thu Sep 04 23:25:07 EDT 2025 Fri Jul 25 09:07:54 EDT 2025 Thu Apr 03 07:02:44 EDT 2025 Thu Apr 24 22:57:00 EDT 2025 Tue Jul 01 03:46:26 EDT 2025 Fri Feb 21 02:39:36 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c513t-7a107deecacf0d2e4bae624822f88043ee0b5ebacb920359c2506f87c12f12923 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-5104-6231 |
| OpenAccessLink | https://doi.org/10.1007/s40265-024-02067-8 |
| PMID | 38902571 |
| PQID | 3091182761 |
| PQPubID | 34797 |
| PageCount | 13 |
| ParticipantIDs | swepub_primary_oai_gup_ub_gu_se_339593 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11289173 proquest_miscellaneous_3070839324 proquest_journals_3091182761 pubmed_primary_38902571 crossref_citationtrail_10_1007_s40265_024_02067_8 crossref_primary_10_1007_s40265_024_02067_8 springer_journals_10_1007_s40265_024_02067_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-07-01 |
| PublicationDateYYYYMMDD | 2024-07-01 |
| PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Cham |
| PublicationPlace_xml | – name: Cham – name: New Zealand – name: Auckland |
| PublicationTitle | Drugs (New York, N.Y.) |
| PublicationTitleAbbrev | Drugs |
| PublicationTitleAlternate | Drugs |
| PublicationYear | 2024 |
| Publisher | Springer International Publishing Springer Nature B.V |
| Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
| References | AlbertMSDeKoskySTDicksonDDuboisBFeldmanHHFoxNCThe diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s diseaseAlzheimer’s Dement.2011727027910.1016/j.jalz.2011.03.008 ForteaJPeguerolesJAlcoleaDBelbinODols-IcardoOVaque-AlcazarLAPOE4 homozygozity represents a distinct genetic form of Alzheimer's diseaseNat Med2024305128412911:CAS:528:DC%2BB2cXpvFOks7k%3D10.1038/s41591-024-02931-w38710950 WithingtonCGTurnerRSAmyloid-related imaging abnormalities with anti- amyloid antibodies for the treatment of dementia due to Alzheimer’s diseaseFront Neurol20221310.3389/fneur.2022.862369354014128985815 RosesADApolipoprotein E alleles as risk factors in Alzheimer's diseaseAnnu Rev Med1996473874001:CAS:528:DyaK28XitlSntLs%3D10.1146/annurev.med.47.1.3878712790 KarikariTKPascoalTAAshtonNJJanelidzeSBenedetALRodriguezJLBlood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohortsLancet Neurol2020194224331:CAS:528:DC%2BB3cXnslOgu78%3D10.1016/s1474-4422(20)30071-532333900 CummingsJLApostolovaLRabinoviciGDAtriAAisenPGreenbergSLecanemab: appropriate use recommendationsJ Prev Alzheimers Dis.20231033623771:STN:280:DC%2BB2svgsFKgsw%3D%3D10.14283/jpad.2023.303735727610313141 BarakosJPurcellDSuhyJChalkiasSBurkettPMarsica GrassiCDetection and management of amyloid- related imaging abnormalities in patients with Alzheimer’s disease treated with anti-amyloid beta therapyJ Prev Alzheimers Dis.202292112201:STN:280:DC%2BB2MrptlyktQ%3D%3D10.14283/jpad.2022.2135542992 TolarMHeyJAPowerAAbushakraSThe single toxin origin of Alzheimer's disease and other neurodegenerative disorders enables targeted approach to treatment and preventionInt J Mol Sci202425527271:CAS:528:DC%2BB2cXmtF2is7o%3D10.3390/ijms250527273847397510932387 AbushakraSPorsteinssonAPSabbaghMBracoudLSchaererJPowerAAPOE ε4/ε4 homozygotes with early Alzheimer’s disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive declineAlzheimers Dement (N Y).20206110.1002/trc2.1211733304988 GreenbergSMBacskaiBJHernandez-GuillamonMPruzinJSperlingRvan VeluwSJCerebral amyloid angiopathy and Alzheimer disease—one peptide, two pathwaysNat Rev Neurol20201630421:CAS:528:DC%2BC1MXitlyntL3N10.1038/s41582-019-0281-231827267 HanssonOBiomarkers for neurodegenerative diseasesNat Med2021279549631:CAS:528:DC%2BB3MXht1CisbbM10.1038/s41591-021-01382-x34083813 LiangCSavinovSNFejzoJEylesSJChenJModulation of amyloid-beta42 conformation by small molecules through nonspecific bindingJ Chem Theory Comput20191510516951741:CAS:528:DC%2BC1MXhs12jt77L10.1021/acs.jctc.9b00599314761246783347 HampelHElhageAChoMApostolovaLGNicollJARAtriAAmyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristicsBrain20231464414442410.1093/brain/awad1883728011010629981 WechslerDWechsler adult intelligence scale-revised manual1981New YorkThe Psychological Corporation PetersenRCAisenPSBeckettLADonohueMCGamstACHarveyetDJAlzheimer’s disease neuroimaging initiative (ADNI): clinical characterizationNeurology20107420120910.1212/WNL.0b013e3181cb3e25200427042809036 Budd HaeberleinSAisenPSBarkhofFChalkiasSChenTCohenSTwo randomized phase 3 studies of aducanumab in early Alzheimer's diseaseJ Prev Alzheimers Dis.2022921972101:STN:280:DC%2BB2MrptlyktA%3D%3D10.14283/jpad.2022.3035542991 RoherAEEshCLKokjohnTACastañoEMVan VickleGDKalbackWMAβ peptides in human plasma and tissues and their significance for Alzheimer’s diseaseAlzheimers Dement20095118291:CAS:528:DC%2BD1MXit1Cmsbg%3D10.1016/j.jalz.2008.10.00419118806 FolsteinMFFolsteinSEMcHughPR"Mini-mental state". A practical method for grading the cognitive state of patients for the clinicianJ Psychiatr Res19751231891981:STN:280:DyaE28%2FntFKjtw%3D%3D10.1016/0022-3956(75)90026-61202204 AbushakraSEffects of oral ALZ-801 on plasma and MRI biomarkers in APOE4 carriers with Early AD: 52-week analysis from Phase 2 biomarker study2022San FranciscoClinical Trials on Alzheimer's Disease (CTAD) TolarMAbushakraSHeyJAPorsteinssonASabbaghMAducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approvalAlzheimers Res Ther.2020121951:CAS:528:DC%2BB3cXhs1Sgsr3F10.1186/s13195-020-00663-w327879717424995 van DyckCHSwansonCJAisenPBatemanRJChenCGeeMLecanemab in early Alzheimer’s diseaseN Engl J Med202338892110.1056/NEJMoa221294836449413 MoscosoAGrotheMJAshtonNJKarikariTKLantero RodríguezJSnellmanALongitudinal associations of blood phosphorylated tau181 and neurofilament light chain with neurodegeneration in Alzheimer’s diseaseJAMA Neurol202178439640610.1001/jamaneurol.2020.498633427873 AbushakraSMandelbaumRBarakosJScheltensPPorsteinssonAPWatsonDPrevalence of amyloid-related imaging abnormalities in APOE4/4 homozygotes with early Alzheimer’s disease (AD): baseline findings from ongoing clinical trials of the oral anti-amyloid agent ALZ-801 (valiltramiprosate) (P5–6.003)Neurology202310.1212/WNL.000000000020355 O'BryantSEWaringSCCullumCMHallJLacritzLMassmanPJStaging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium studyArch Neurol20086581091109510.1001/archneur.65.8.1091186950593409562 AngioniDHanssonOBatemanRJRabeCToloueMBraunsteinJBCan we use blood biomarkers as entry criteria and for monitoring drug treatment effects in clinical trials? A report from the EU/US CTAD Task ForceJ Prev Alzheimers Dis.2023104184251:STN:280:DC%2BB2svgsFKgtQ%3D%3D10.14283/jpad.2023.6837357282 FleisherASChenKLiuXAyutyanontNRoontivaAThiyyaguraPApolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer diseaseNeurobiol Aging2013341121:CAS:528:DC%2BC38XnslKktLY%3D10.1016/j.neurobiolaging.2012.04.01722633529 SperlingRAJackCRJrBlackSEFroschMPGreenbergSMHymanBTAmyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable WorkgroupAlzheimers Dement2011736738510.1016/j.jalz.2011.05.235121784348 HeyJAYuJYVersavelMAbushakraSKocisPPowerAClinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer's diseaseClin Pharmacokinet20185733153331:CAS:528:DC%2BC2sXhslWjurbP10.1007/s40262-017-0608-329063518 AbushakraSPorsteinssonAVellasBCummingsJGauthierSHeyJAClinical benefits of tramiprosate in Alzheimer’s disease are associated with higher number of APOE4 alleles: the “APOE4 gene-dose effect”J Prev Alz Dis.2016342192281:STN:280:DC%2BC1M3ntlKisA%3D%3D10.14283/jpad.2016.115 Jack CR, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer’s Association Workgroup. 2023. JackCRBennettDABlennowKCarrilloMCDunnBHaeberleinSBNIA-AA research framework: toward a biological definition of Alzheimer’s diseaseAlzheimer’s Dement.20181453556210.1016/j.jalz.2018.02.018 CogswellPMLundtESTherneauTMWisteHJGraff-RadfordJAlgeciras-SchimnichAModeling the temporal evolution of plasma p-tau in relation to amyloid beta and tau PETAlzheimers Dement2024202122512381:CAS:528:DC%2BB3sXisVans7jK10.1002/alz.1353937963289 SimsJRZimmerJAEvansCDLuMArdayfioPSparksJDonanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trialJAMA202333065125271:CAS:528:DC%2BB3sXhs1KhurvM10.1001/jama.2023.132393745914110352931 JansenWJOssenkoppeleRKnolDLTijmsBMScheltensPVerheyFRJPrevalence of cerebral amyloid pathology in persons without dementia: a meta-analysisJAMA20153131939194910.1001/jama.2015.4669259884634517678 LezakMDHowiesonDBLoringDWNeuropsychological assessment20044New YorkOxford University Press McKhannGKnopmanDSChertkowHHymannBJackCRKawasCThe diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s diseaseAlzheimers Dement2011726326910.1016/j.jalz.2011.03.00521514250 La JoieRVisaniAVLesman-SegevOHBakerSLEdwardsLIaccarinoLAssociation of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PETNeurology2021965e650e6611:CAS:528:DC%2BB3MXhslGns77I10.1212/WNL.0000000000011270332622287884991 RannikmäeKKalariaRNGreenbergSMChuiHCSchmittFASamarasekeraNAPOE associations with severe CAA-associated vasculopathic changes: collaborative meta-analysisJ Neurol Neurosurg Psychiatry20148530030510.1136/jnnp-2013-30648524163429 AbushakraSPorsteinssonAScheltensPSadowskyCVellasBCummingsJClinical effects of tramiprosate in APOE4/4 homozygous patients with mild Alzheimer’s disease suggest disease modification potentialJ Prev Alzeimers Dis.2017431491561:STN:280:DC%2BC1M3lslSjsA%3D%3D10.14283/jpad.2017.26 WardACreanSMercaldiCJCollinsJMBoydDCookMNPrevalence of Apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with alzheimer’s disease: a systematic review and meta-analysisNeuroepidemiology20123811710.1159/00033460722179327 CorderEHSaundersAMStrittmatterWJSchmechelDEGaskellPCSmallGWGene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset familiesScience199326151239219231:CAS:528:DyaK3sXmtVWjur8%3D10.1126/science.83464438346443 Tarasoff-ConwayJCarareROOsorioRSGlodzikLButlerTFieremansEClearance systems in the brain - implications for Alzheimer diseaseNat Rev Neurol20151184574701:CAS:528:DC%2BC2MXht1Wqt73N10.1038/nrneurol.2015.119261952564694579 KocisPTolarMYuJSinkoWRaySBlennowKElucidating the abeta42 anti-aggregation mechanism of action of tramiprosate in Alzheimer's disease: integrating molecular analytical Methods, pharmacokinetic and clinical dataCNS Drugs20173164955091:CAS:528:DC%2BC2sXmsVakt7w%3D10.1007/s40263-017-0434-z284359855488121 HanssonOSeibylJStomrudEZetterbergHTrojanowskiJQBittnerTCSF biomarkers of Alzheimer’s disease concord with amyloid-β S Abushakra (2067_CR22) 2017; 4 K Blennow (2067_CR38) 2023; 19 D Wechsler (2067_CR41) 1981 DM Wilcock (2067_CR9) 2004; 1 JA Hey (2067_CR20) 2018; 57 G McKhann (2067_CR36) 2011; 7 AE Roher (2067_CR51) 2009; 5 2067_CR30 J Barakos (2067_CR8) 2022; 9 TA Salthouse (2067_CR43) 1978; 33 WJ Jansen (2067_CR25) 2015; 313 RC Petersen (2067_CR45) 2010; 74 2067_CR1 K Rannikmäe (2067_CR11) 2014; 85 O Hansson (2067_CR28) 2018; 14 TK Karikari (2067_CR33) 2020; 19 PM Cogswell (2067_CR53) 2024; 20 JR Sims (2067_CR55) 2023; 330 AD Roses (2067_CR3) 1996; 47 M Tolar (2067_CR15) 2021; 22 D Mungas (2067_CR48) 2005; 65 R La Joie (2067_CR54) 2021; 96 C Liang (2067_CR19) 2019; 15 EH Corder (2067_CR2) 1993; 261 S Abushakra (2067_CR39) 2020; 6 MD Lezak (2067_CR42) 2004 J Tarasoff-Conway (2067_CR50) 2015; 11 RA Sperling (2067_CR6) 2011; 7 AS Fleisher (2067_CR24) 2013; 34 CG Withington (2067_CR13) 2022; 13 JL Cummings (2067_CR56) 2023; 10 S Abushakra (2067_CR40) 2023 MF Folstein (2067_CR44) 1975; 12 A Moscoso (2067_CR32) 2021; 78 P Kocis (2067_CR17) 2017; 31 2067_CR57 J Fortea (2067_CR26) 2024; 30 H Hampel (2067_CR7) 2023; 146 F Gervais (2067_CR52) 2007; 28 M Tolar (2067_CR16) 2024; 25 SE O'Bryant (2067_CR47) 2008; 65 S Abushakra (2067_CR46) 2022 SM Greenberg (2067_CR10) 2020; 16 MS Albert (2067_CR37) 2011; 7 O Hansson (2067_CR29) 2021; 27 CH van Dyck (2067_CR5) 2023; 388 T Hashimoto (2067_CR23) 2012; 32 N Mattsson-Carlgren (2067_CR31) 2020; 6 M Tolar (2067_CR14) 2020; 12 WJ Jansen (2067_CR12) 2022; 79 JA Hey (2067_CR18) 2018; 32 S Abushakra (2067_CR21) 2016; 3 S Budd Haeberlein (2067_CR35) 2022; 9 D Angioni (2067_CR49) 2023; 10 CR Jack (2067_CR27) 2018; 14 A Ward (2067_CR4) 2012; 38 J Therriault (2067_CR34) 2022; 80 |
| References_xml | – reference: BlennowKGalaskoDPerneczkyRQuevencoFCvan der FlierWMAkinwonmiAThe potential clinical value of plasma biomarkers in Alzheimer’s diseaseAlzheimers Dement202319580558161:CAS:528:DC%2BB3sXhvFems7vM10.1002/alz.1345537694991 – reference: JansenWJOssenkoppeleRKnolDLTijmsBMScheltensPVerheyFRJPrevalence of cerebral amyloid pathology in persons without dementia: a meta-analysisJAMA20153131939194910.1001/jama.2015.4669259884634517678 – reference: SalthouseTAThe role of memory in the age decline in digit-symbol substitution performanceJ Gerontol1978332322381:STN:280:DyaE1c7htVWgsA%3D%3D10.1093/geronj/33.2.232637915 – reference: CogswellPMLundtESTherneauTMWisteHJGraff-RadfordJAlgeciras-SchimnichAModeling the temporal evolution of plasma p-tau in relation to amyloid beta and tau PETAlzheimers Dement2024202122512381:CAS:528:DC%2BB3sXisVans7jK10.1002/alz.1353937963289 – reference: HeyJAKocisPHortJAbushakraSPowerAVyhnalekMDiscovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brainCNS Drugs20183298498611:CAS:528:DC%2BC1cXhsVCgu7fE10.1007/s40263-018-0554-0300765396153967 – reference: KarikariTKPascoalTAAshtonNJJanelidzeSBenedetALRodriguezJLBlood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohortsLancet Neurol2020194224331:CAS:528:DC%2BB3cXnslOgu78%3D10.1016/s1474-4422(20)30071-532333900 – reference: MungasDHarveyDReedBRJagustWJDeCarliCBeckettLLongitudinal volumetric MRI change and rate of cognitive declineNeurology2005655655711:STN:280:DC%2BD2MvkvFCgsg%3D%3D10.1212/01.wnl.0000172913.88973.0d16116117 – reference: JackCRBennettDABlennowKCarrilloMCDunnBHaeberleinSBNIA-AA research framework: toward a biological definition of Alzheimer’s diseaseAlzheimer’s Dement.20181453556210.1016/j.jalz.2018.02.018 – reference: WechslerDWechsler adult intelligence scale-revised manual1981New YorkThe Psychological Corporation – reference: La JoieRVisaniAVLesman-SegevOHBakerSLEdwardsLIaccarinoLAssociation of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PETNeurology2021965e650e6611:CAS:528:DC%2BB3MXhslGns77I10.1212/WNL.0000000000011270332622287884991 – reference: JansenWJJanssenOTijmsBMVosSJBOssenkoppeleRVisserPJPrevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrumJAMA Neurol20227922824310.1001/jamaneurol.2021.521635099509 – reference: TolarMAbushakraSHeyJAPorsteinssonASabbaghMAducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approvalAlzheimers Res Ther.2020121951:CAS:528:DC%2BB3cXhs1Sgsr3F10.1186/s13195-020-00663-w327879717424995 – reference: SimsJRZimmerJAEvansCDLuMArdayfioPSparksJDonanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trialJAMA202333065125271:CAS:528:DC%2BB3sXhs1KhurvM10.1001/jama.2023.132393745914110352931 – reference: MoscosoAGrotheMJAshtonNJKarikariTKLantero RodríguezJSnellmanALongitudinal associations of blood phosphorylated tau181 and neurofilament light chain with neurodegeneration in Alzheimer’s diseaseJAMA Neurol202178439640610.1001/jamaneurol.2020.498633427873 – reference: RosesADApolipoprotein E alleles as risk factors in Alzheimer's diseaseAnnu Rev Med1996473874001:CAS:528:DyaK28XitlSntLs%3D10.1146/annurev.med.47.1.3878712790 – reference: HampelHElhageAChoMApostolovaLGNicollJARAtriAAmyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristicsBrain20231464414442410.1093/brain/awad1883728011010629981 – reference: AlbertMSDeKoskySTDicksonDDuboisBFeldmanHHFoxNCThe diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s diseaseAlzheimer’s Dement.2011727027910.1016/j.jalz.2011.03.008 – reference: Mattsson-CarlgrenNAnderssonEJanelidzeSOssenkoppeleRInselPStrandbergOAβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s diseaseSci Adv2020616eaaz23871:CAS:528:DC%2BB3cXitFGnurfL10.1126/sciadv.aaz2387324264547159908 – reference: TherriaultJVermeirenMServaesSTissotCZimmerERBenedetALAssociation of phosphorylated tau biomarkers with amyloid-PET vs with tau-PETJAMA Neurol202280218819910.1001/jamaneurol.2022.44859856704 – reference: TolarMHeyJAPowerAAbushakraSThe single toxin origin of Alzheimer's disease and other neurodegenerative disorders enables targeted approach to treatment and preventionInt J Mol Sci202425527271:CAS:528:DC%2BB2cXmtF2is7o%3D10.3390/ijms250527273847397510932387 – reference: LezakMDHowiesonDBLoringDWNeuropsychological assessment20044New YorkOxford University Press – reference: van DyckCHSwansonCJAisenPBatemanRJChenCGeeMLecanemab in early Alzheimer’s diseaseN Engl J Med202338892110.1056/NEJMoa221294836449413 – reference: RoherAEEshCLKokjohnTACastañoEMVan VickleGDKalbackWMAβ peptides in human plasma and tissues and their significance for Alzheimer’s diseaseAlzheimers Dement20095118291:CAS:528:DC%2BD1MXit1Cmsbg%3D10.1016/j.jalz.2008.10.00419118806 – reference: Budd HaeberleinSAisenPSBarkhofFChalkiasSChenTCohenSTwo randomized phase 3 studies of aducanumab in early Alzheimer's diseaseJ Prev Alzheimers Dis.2022921972101:STN:280:DC%2BB2MrptlyktA%3D%3D10.14283/jpad.2022.3035542991 – reference: HanssonOSeibylJStomrudEZetterbergHTrojanowskiJQBittnerTCSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohortsAlzheimers Dement2018141470148110.1016/j.jalz.2018.01.01029499171 – reference: LiangCSavinovSNFejzoJEylesSJChenJModulation of amyloid-beta42 conformation by small molecules through nonspecific bindingJ Chem Theory Comput20191510516951741:CAS:528:DC%2BC1MXhs12jt77L10.1021/acs.jctc.9b00599314761246783347 – reference: CummingsJLApostolovaLRabinoviciGDAtriAAisenPGreenbergSLecanemab: appropriate use recommendationsJ Prev Alzheimers Dis.20231033623771:STN:280:DC%2BB2svgsFKgsw%3D%3D10.14283/jpad.2023.303735727610313141 – reference: ForteaJPeguerolesJAlcoleaDBelbinODols-IcardoOVaque-AlcazarLAPOE4 homozygozity represents a distinct genetic form of Alzheimer's diseaseNat Med2024305128412911:CAS:528:DC%2BB2cXpvFOks7k%3D10.1038/s41591-024-02931-w38710950 – reference: FleisherASChenKLiuXAyutyanontNRoontivaAThiyyaguraPApolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer diseaseNeurobiol Aging2013341121:CAS:528:DC%2BC38XnslKktLY%3D10.1016/j.neurobiolaging.2012.04.01722633529 – reference: RannikmäeKKalariaRNGreenbergSMChuiHCSchmittFASamarasekeraNAPOE associations with severe CAA-associated vasculopathic changes: collaborative meta-analysisJ Neurol Neurosurg Psychiatry20148530030510.1136/jnnp-2013-30648524163429 – reference: AbushakraSPorsteinssonAScheltensPSadowskyCVellasBCummingsJClinical effects of tramiprosate in APOE4/4 homozygous patients with mild Alzheimer’s disease suggest disease modification potentialJ Prev Alzeimers Dis.2017431491561:STN:280:DC%2BC1M3lslSjsA%3D%3D10.14283/jpad.2017.26 – reference: Tarasoff-ConwayJCarareROOsorioRSGlodzikLButlerTFieremansEClearance systems in the brain - implications for Alzheimer diseaseNat Rev Neurol20151184574701:CAS:528:DC%2BC2MXht1Wqt73N10.1038/nrneurol.2015.119261952564694579 – reference: WardACreanSMercaldiCJCollinsJMBoydDCookMNPrevalence of Apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with alzheimer’s disease: a systematic review and meta-analysisNeuroepidemiology20123811710.1159/00033460722179327 – reference: AbushakraSEffects of oral ALZ-801 on plasma and MRI biomarkers in APOE4 carriers with Early AD: 52-week analysis from Phase 2 biomarker study2022San FranciscoClinical Trials on Alzheimer's Disease (CTAD) – reference: HeyJAYuJYVersavelMAbushakraSKocisPPowerAClinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer's diseaseClin Pharmacokinet20185733153331:CAS:528:DC%2BC2sXhslWjurbP10.1007/s40262-017-0608-329063518 – reference: GervaisFPaquetteJMorissetteCKrzywkowskiPYuMAzziMTargeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosisNeurobiol Aging2007285375471:CAS:528:DC%2BD2sXitFyks74%3D10.1016/j.neurobiolaging.2023.04.00316675063 – reference: McKhannGKnopmanDSChertkowHHymannBJackCRKawasCThe diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s diseaseAlzheimers Dement2011726326910.1016/j.jalz.2011.03.00521514250 – reference: WithingtonCGTurnerRSAmyloid-related imaging abnormalities with anti- amyloid antibodies for the treatment of dementia due to Alzheimer’s diseaseFront Neurol20221310.3389/fneur.2022.862369354014128985815 – reference: AbushakraSPorsteinssonAPSabbaghMBracoudLSchaererJPowerAAPOE ε4/ε4 homozygotes with early Alzheimer’s disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive declineAlzheimers Dement (N Y).20206110.1002/trc2.1211733304988 – reference: FolsteinMFFolsteinSEMcHughPR"Mini-mental state". A practical method for grading the cognitive state of patients for the clinicianJ Psychiatr Res19751231891981:STN:280:DyaE28%2FntFKjtw%3D%3D10.1016/0022-3956(75)90026-61202204 – reference: AbushakraSPorsteinssonAVellasBCummingsJGauthierSHeyJAClinical benefits of tramiprosate in Alzheimer’s disease are associated with higher number of APOE4 alleles: the “APOE4 gene-dose effect”J Prev Alz Dis.2016342192281:STN:280:DC%2BC1M3ntlKisA%3D%3D10.14283/jpad.2016.115 – reference: O'BryantSEWaringSCCullumCMHallJLacritzLMassmanPJStaging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium studyArch Neurol20086581091109510.1001/archneur.65.8.1091186950593409562 – reference: GreenbergSMBacskaiBJHernandez-GuillamonMPruzinJSperlingRvan VeluwSJCerebral amyloid angiopathy and Alzheimer disease—one peptide, two pathwaysNat Rev Neurol20201630421:CAS:528:DC%2BC1MXitlyntL3N10.1038/s41582-019-0281-231827267 – reference: KocisPTolarMYuJSinkoWRaySBlennowKElucidating the abeta42 anti-aggregation mechanism of action of tramiprosate in Alzheimer's disease: integrating molecular analytical Methods, pharmacokinetic and clinical dataCNS Drugs20173164955091:CAS:528:DC%2BC2sXmsVakt7w%3D10.1007/s40263-017-0434-z284359855488121 – reference: AbushakraSMandelbaumRBarakosJScheltensPPorsteinssonAPWatsonDPrevalence of amyloid-related imaging abnormalities in APOE4/4 homozygotes with early Alzheimer’s disease (AD): baseline findings from ongoing clinical trials of the oral anti-amyloid agent ALZ-801 (valiltramiprosate) (P5–6.003)Neurology202310.1212/WNL.000000000020355 – reference: TolarMHeyJPowerAAbushakraSNeurotoxic soluble amyloid oligomers drive Alzheimer's pathogenesis and represent a clinically validated target for slowing disease progressionInt J Mol Sci2021221263551:CAS:528:DC%2BB3MXhslGltbjN10.3390/ijms22126355341985828231952 – reference: HashimotoTSerrano-PozoAHoriYAdamsKWTakedaSBanerjiAOApolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid peptideJ Neurosci20123215181151921:CAS:528:DC%2BC38Xhs1ShsrzN10.1523/JNEUROSCI.1542-12.2012231004393493562 – reference: SperlingRAJackCRJrBlackSEFroschMPGreenbergSMHymanBTAmyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable WorkgroupAlzheimers Dement2011736738510.1016/j.jalz.2011.05.235121784348 – reference: Jack CR, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer’s Association Workgroup. 2023. – reference: AngioniDHanssonOBatemanRJRabeCToloueMBraunsteinJBCan we use blood biomarkers as entry criteria and for monitoring drug treatment effects in clinical trials? A report from the EU/US CTAD Task ForceJ Prev Alzheimers Dis.2023104184251:STN:280:DC%2BB2svgsFKgtQ%3D%3D10.14283/jpad.2023.6837357282 – reference: Alzheimer’s Association Facts and Figures. 2024. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. – reference: Hey JA, Yu JY, Abushakra S, Schaefer JF, Power A, Kesslak P, et al. Analysis of cerebrospinal fluid, plasma β-amyloid biomarkers and cognition from 2-year phase 2 trial evaluating oral ALZ-801/valiltramiprosate in APOE4 carriers with early Alzheimer’s disease using quantitative systems pharmacology model. Drugs 2024;84. https://doi.org/10.1007/s40265-024-02068-7. – reference: WilcockDMRojianiARosenthalASubbaraoSFreemanMJGordonMNPassive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhageJ Neuroinflamm20041241:CAS:528:DC%2BD2MXjs1elsLk%3D10.1186/1742-2094-1-24 – reference: PetersenRCAisenPSBeckettLADonohueMCGamstACHarveyetDJAlzheimer’s disease neuroimaging initiative (ADNI): clinical characterizationNeurology20107420120910.1212/WNL.0b013e3181cb3e25200427042809036 – reference: CorderEHSaundersAMStrittmatterWJSchmechelDEGaskellPCSmallGWGene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset familiesScience199326151239219231:CAS:528:DyaK3sXmtVWjur8%3D10.1126/science.83464438346443 – reference: HanssonOBiomarkers for neurodegenerative diseasesNat Med2021279549631:CAS:528:DC%2BB3MXht1CisbbM10.1038/s41591-021-01382-x34083813 – reference: BarakosJPurcellDSuhyJChalkiasSBurkettPMarsica GrassiCDetection and management of amyloid- related imaging abnormalities in patients with Alzheimer’s disease treated with anti-amyloid beta therapyJ Prev Alzheimers Dis.202292112201:STN:280:DC%2BB2MrptlyktQ%3D%3D10.14283/jpad.2022.2135542992 – volume: 19 start-page: 5805 year: 2023 ident: 2067_CR38 publication-title: Alzheimers Dement doi: 10.1002/alz.13455 – volume: 57 start-page: 315 issue: 3 year: 2018 ident: 2067_CR20 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-017-0608-3 – volume-title: Effects of oral ALZ-801 on plasma and MRI biomarkers in APOE4 carriers with Early AD: 52-week analysis from Phase 2 biomarker study year: 2022 ident: 2067_CR46 – volume: 20 start-page: 1225 issue: 2 year: 2024 ident: 2067_CR53 publication-title: Alzheimers Dement doi: 10.1002/alz.13539 – volume: 30 start-page: 1284 issue: 5 year: 2024 ident: 2067_CR26 publication-title: Nat Med doi: 10.1038/s41591-024-02931-w – volume: 12 start-page: 189 issue: 3 year: 1975 ident: 2067_CR44 publication-title: J Psychiatr Res doi: 10.1016/0022-3956(75)90026-6 – volume: 13 year: 2022 ident: 2067_CR13 publication-title: Front Neurol doi: 10.3389/fneur.2022.862369 – volume: 80 start-page: 188 issue: 2 year: 2022 ident: 2067_CR34 publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2022.4485 – volume: 32 start-page: 849 issue: 9 year: 2018 ident: 2067_CR18 publication-title: CNS Drugs doi: 10.1007/s40263-018-0554-0 – volume: 6 start-page: eaaz2387 issue: 16 year: 2020 ident: 2067_CR31 publication-title: Sci Adv doi: 10.1126/sciadv.aaz2387 – volume: 34 start-page: 1 year: 2013 ident: 2067_CR24 publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2012.04.017 – volume: 19 start-page: 422 year: 2020 ident: 2067_CR33 publication-title: Lancet Neurol doi: 10.1016/s1474-4422(20)30071-5 – volume: 11 start-page: 457 issue: 8 year: 2015 ident: 2067_CR50 publication-title: Nat Rev Neurol doi: 10.1038/nrneurol.2015.119 – volume: 74 start-page: 201 year: 2010 ident: 2067_CR45 publication-title: Neurology doi: 10.1212/WNL.0b013e3181cb3e25 – volume: 146 start-page: 4414 year: 2023 ident: 2067_CR7 publication-title: Brain doi: 10.1093/brain/awad188 – volume: 25 start-page: 2727 issue: 5 year: 2024 ident: 2067_CR16 publication-title: Int J Mol Sci doi: 10.3390/ijms25052727 – volume: 65 start-page: 1091 issue: 8 year: 2008 ident: 2067_CR47 publication-title: Arch Neurol doi: 10.1001/archneur.65.8.1091 – volume: 6 issue: 1 year: 2020 ident: 2067_CR39 publication-title: Alzheimers Dement (N Y). doi: 10.1002/trc2.12117 – volume: 7 start-page: 367 year: 2011 ident: 2067_CR6 publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2011.05.2351 – volume: 7 start-page: 263 year: 2011 ident: 2067_CR36 publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2011.03.005 – year: 2023 ident: 2067_CR40 publication-title: Neurology doi: 10.1212/WNL.000000000020355 – volume: 15 start-page: 5169 issue: 10 year: 2019 ident: 2067_CR19 publication-title: J Chem Theory Comput doi: 10.1021/acs.jctc.9b00599 – volume: 32 start-page: 15181 year: 2012 ident: 2067_CR23 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.1542-12.2012 – volume: 388 start-page: 9 year: 2023 ident: 2067_CR5 publication-title: N Engl J Med doi: 10.1056/NEJMoa2212948 – volume: 31 start-page: 495 issue: 6 year: 2017 ident: 2067_CR17 publication-title: CNS Drugs doi: 10.1007/s40263-017-0434-z – volume: 65 start-page: 565 year: 2005 ident: 2067_CR48 publication-title: Neurology doi: 10.1212/01.wnl.0000172913.88973.0d – volume: 16 start-page: 30 year: 2020 ident: 2067_CR10 publication-title: Nat Rev Neurol doi: 10.1038/s41582-019-0281-2 – volume: 12 start-page: 95 issue: 1 year: 2020 ident: 2067_CR14 publication-title: Alzheimers Res Ther. doi: 10.1186/s13195-020-00663-w – volume: 5 start-page: 18 issue: 1 year: 2009 ident: 2067_CR51 publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2008.10.004 – volume: 96 start-page: e650 issue: 5 year: 2021 ident: 2067_CR54 publication-title: Neurology doi: 10.1212/WNL.0000000000011270 – volume: 47 start-page: 387 year: 1996 ident: 2067_CR3 publication-title: Annu Rev Med doi: 10.1146/annurev.med.47.1.387 – volume: 79 start-page: 228 year: 2022 ident: 2067_CR12 publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2021.5216 – ident: 2067_CR30 – volume: 33 start-page: 232 year: 1978 ident: 2067_CR43 publication-title: J Gerontol doi: 10.1093/geronj/33.2.232 – volume: 261 start-page: 921 issue: 5123 year: 1993 ident: 2067_CR2 publication-title: Science doi: 10.1126/science.8346443 – volume: 14 start-page: 1470 year: 2018 ident: 2067_CR28 publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2018.01.010 – volume: 3 start-page: 219 issue: 4 year: 2016 ident: 2067_CR21 publication-title: J Prev Alz Dis. doi: 10.14283/jpad.2016.115 – volume: 85 start-page: 300 year: 2014 ident: 2067_CR11 publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp-2013-306485 – volume: 78 start-page: 396 issue: 4 year: 2021 ident: 2067_CR32 publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2020.4986 – volume: 22 start-page: 6355 issue: 12 year: 2021 ident: 2067_CR15 publication-title: Int J Mol Sci doi: 10.3390/ijms22126355 – volume: 313 start-page: 1939 year: 2015 ident: 2067_CR25 publication-title: JAMA doi: 10.1001/jama.2015.4669 – ident: 2067_CR1 – volume: 4 start-page: 149 issue: 3 year: 2017 ident: 2067_CR22 publication-title: J Prev Alzeimers Dis. doi: 10.14283/jpad.2017.26 – volume: 14 start-page: 535 year: 2018 ident: 2067_CR27 publication-title: Alzheimer’s Dement. doi: 10.1016/j.jalz.2018.02.018 – volume-title: Neuropsychological assessment year: 2004 ident: 2067_CR42 – volume-title: Wechsler adult intelligence scale-revised manual year: 1981 ident: 2067_CR41 – volume: 1 start-page: 24 year: 2004 ident: 2067_CR9 publication-title: J Neuroinflamm doi: 10.1186/1742-2094-1-24 – volume: 10 start-page: 362 issue: 3 year: 2023 ident: 2067_CR56 publication-title: J Prev Alzheimers Dis. doi: 10.14283/jpad.2023.30 – volume: 9 start-page: 211 year: 2022 ident: 2067_CR8 publication-title: J Prev Alzheimers Dis. doi: 10.14283/jpad.2022.21 – volume: 7 start-page: 270 year: 2011 ident: 2067_CR37 publication-title: Alzheimer’s Dement. doi: 10.1016/j.jalz.2011.03.008 – volume: 27 start-page: 954 year: 2021 ident: 2067_CR29 publication-title: Nat Med doi: 10.1038/s41591-021-01382-x – ident: 2067_CR57 doi: 10.1007/s40265-024-02068-7 – volume: 10 start-page: 418 year: 2023 ident: 2067_CR49 publication-title: J Prev Alzheimers Dis. doi: 10.14283/jpad.2023.68 – volume: 9 start-page: 197 issue: 2 year: 2022 ident: 2067_CR35 publication-title: J Prev Alzheimers Dis. doi: 10.14283/jpad.2022.30 – volume: 28 start-page: 537 year: 2007 ident: 2067_CR52 publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2023.04.003 – volume: 330 start-page: 512 issue: 6 year: 2023 ident: 2067_CR55 publication-title: JAMA doi: 10.1001/jama.2023.13239 – volume: 38 start-page: 1 year: 2012 ident: 2067_CR4 publication-title: Neuroepidemiology doi: 10.1159/000334607 |
| SSID | ssj0012959 |
| Score | 2.5006108 |
| Snippet | Introduction
ALZ-801/valiltramiprosate is a small-molecule oral inhibitor of beta amyloid (Aβ) aggregation and oligomer formation being studied in a phase 2... ALZ-801/valiltramiprosate is a small-molecule oral inhibitor of beta amyloid (Aβ) aggregation and oligomer formation being studied in a phase 2 trial in APOE4... Introduction ALZ-801/valiltramiprosate is a small-molecule oral inhibitor of beta amyloid (Aβ) aggregation and oligomer formation being studied in a phase 2... Introduction ALZ-801/valiltramiprosate is a small-molecule oral inhibitor of beta amyloid (A beta) aggregation and oligomer formation being studied in a phase... |
| SourceID | swepub pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 811 |
| SubjectTerms | Abnormalities Administration, Oral Adverse events Aged Aged, 80 and over Alzheimer Disease - blood Alzheimer Disease - diagnostic imaging Alzheimer Disease - drug therapy Alzheimer Disease - physiopathology Alzheimer's disease Amyloid beta-Peptides Apolipoprotein E4 Apolipoprotein E4 - genetics Apolipoproteins Atrophy Auditory discrimination learning Biomarkers Biomarkers - blood Brain Brain research Cerebrospinal fluid Cholinesterase Cholinesterase inhibitors Clinical medicine Cognition Cognition & reasoning Cognition - drug effects Cognitive ability Dementia Dementia disorders Drug dosages Edema Evaluation FDA approval Female Genotypes Health services Heterozygote Heterozygotes Hippocampus Hippocampus - diagnostic imaging Hippocampus - drug effects Hippocampus - pathology Homozygotes Humans Internal Medicine Labels Magnetic Resonance Imaging Male Medical imaging Medicine Medicine & Public Health Middle Aged Neurodegenerative diseases Neuroimaging Neurosciences Neurovetenskaper Oligomers Organ Size Original Original Research Article Pathology Patients Peptide Fragments - blood Pharmacology/Toxicology Pharmacotherapy Plasma tau Proteins Taurine - administration & dosage Taurine - therapeutic use β-Amyloid |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection (ProQuest) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Pb9MwFLZgXLggftMx0ENC5UCiLXZ-lQvqyqYKDVZBNxUukWO_bJXSpDTtYZz4F_jzuPKX8OykqcqkHSq1jRPbyuf3PtvP32PsdYQB9oRM3SzQoesrKd2e7nGXC4V-RgQ7sjmWPn0Oh2f-x0kwaRbcqiascm0TraHWpTJr5PuCHBtxYZp1v5__cE3WKLO72qTQuM3ueMRETOqGaNJOuMiVBTX99bhLND1qDs3Yo3M0bwrN2WSfPmSx3XjbMV1jm9eDJtud0_9URq1nOr7P7jWUEvo1Bh6wW1g8ZN1RrUl95cB4c8SqcqALo41a9dUj9qfWL66gzOB0YZ5z8v3vr9_kUvbPiaPn1IrZlNpZESmFsoAR0e2ZhMNpOTORPQt65KFJMwHD6XxOjpHMSw7n1uY5IAsNgzpAqSzewResVnldFac6vtEog6_UuRzpF0HOARPfQt9PZIq5Y1paIXAYm1ECVEd_dHrkw0AuTJ69CswiMliJZujnPy9xOsPFmwo-1JtOj9nZ8dF4MHSbfA-uCjyxdCNJc1GNqKTKDjRHP5UYcp8oTEZWxheIB2mAqVRpjxvlQUX0LcziSHk8o3fNxRO2U5QFPmOgyTSJNO2ZVV4fgzAmXuUpIbTWgUYtO8xbv-xENWLoJidHnrQyzhYgCQEksQBJ4g57294zr6VAbiy9t8ZQ0piFKtmAuMNetZdpQJtdGllguTJlIqLFRKv9DntaQ66tTthd4YjujrfA2BYwYuHbV4rppRUNJ14d09RcdJizxu2mXTd1o1tje6uKi9U8ob8uVkmFiRBG3Hr35v4-Z3e5HWwm0HmP7SwXK3xBdG6ZvrRj9h_xZUvk priority: 102 providerName: ProQuest |
| Title | Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease |
| URI | https://link.springer.com/article/10.1007/s40265-024-02067-8 https://www.ncbi.nlm.nih.gov/pubmed/38902571 https://www.proquest.com/docview/3091182761 https://www.proquest.com/docview/3070839324 https://pubmed.ncbi.nlm.nih.gov/PMC11289173 https://gup.ub.gu.se/publication/339593 |
| Volume | 84 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NattAEF6aBEovpU1_4jY1Uyi-VEviXf32Zrs2piSOSZ2Q9iJW0igxyJKx7EN66mv0ufoGfZLOSrKMkxLowQis1eyKnZn9VjP7DWMfHLTQkyrgsRXZ3AyV4l7kCS5kiGZMANspaiydjuzhhfnlyrqqaHL0WZg78fujnPY3tj5DbNKPPCt3d9ieRY5Xa3PP7tURA-FZJdRtC06Q3KkOyPxbxvYidA9Z3k-QrKOkdxhFi1Vo8Iw9reAjdMr5fs4eYbrPHp9WAfJ91hqXVNS3Bkw2J6tyA1ow3pBU375gv0va4hyyGM4WWuTJd72OHF0SME9oOLMpDTgnJApZCmPC2DMF3Wk20-k8CxLY1bUlYDidz2k1JJ-SwGXh6AxQaQS9MispSz_BOearpOxI8G9kWPCV3jFBTjpmgE5o4ScqwMTQI8wRBEy0UQBJ74zP-ib01EKX1ctBfzOGgpEZOsmPG5zOcPHn568cPpdRppfsYtCf9Ia8KvDAQ5rCJXcUbT4jxFCF8XEk0AwU2sIkzBKTWzEl4nFgYaDCwBOaajAkvGbHrhO2RUwTLuQrtptmKR4wiMgXySDw9GddEy3bJSDVDqWMosiKMFIN1l7PuB9W7Oe6CEfi17zNhZb4pCV-oSW-22Af62fmJffHg60P14rkV34g9yXBMdrBOXa7wd7Xt8mCdVhGpZitdBuHcDDhaLPBXpd6V3cnizCwQ0-7WxpZN9Ds4Nt30ulNwRJOQNqlvbhsMGOtvJtxPfQarVLBt7q4Xs19-ut65efoS6nZrN_8n9y37IkoLFBnOh-y3eVihe8Izy2DJttxrpwm2-sMut0RXbv90fi8WZj3X_7qRqc |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELaq9gAXxJtAgUGCcCCrdr1vpAolaaqUpmlU0qpwWbxrbxtpsxuyiVA48Rf4Q_wPrvwSxt5HFCrl1kOkJPuwLY9nvrFnviHktSMs4Rks0CKL25oZMqZ53KMaNUJhRgiwHVVj6bhvd8_MjxfWxQb5XebCyLDKUicqRc3TUO6R7xho2BALo9f9YfJNk1Wj5OlqWUKDFaUV-J6iGCsSO47E4ju6cNne4T7O9xtKDzrDdlcrqgxooaUbM81h6AFxIUIWRrucCjNgwqYmGs4IZds0hNgNLBGwMPCo5LsLETTYkeuEOo3QWEriAzQBW6bcQNkkW61Of3BanWNQz8oBuE41dBScIm1HJe-h52bL7GgTP2gzNHfVNF7Du9fDNquz2_94TpVtPLhL7hSgFpq5FN4jGyK5T-qDnBV70YDhMskra0AdBku-7MUD8idnUM4gjeBkKt_T-_L35y80ajvn6CXE2IvxCPuZISyGNIEBAv4xg9YoHcvYoim-siULXUB3NJmgaUYFF8O50roNYAmHdh4ilSbv4VRk8zhvimIbn3EC4RMOLhb4C4W-ATLCBr_3WCDihuxpJoDCUK5TwDaag5OOCW02lZX-MpDb2KBIoqEZ_7gSo7GYvs1gPz_2ekjObkQWHpHNJE3EEwIclaMRBJ7cZzaFZbuI7PTQMDjnFhec1YheTrYfFnTssipI7FdE0kpAfBQQXwmI79bIu-qZSU5Gsvbu7VKG_EIxZf5yGdXIq-oyqhR5TsQSkc7lPQ4CcwT2Zo08zkWuas5Q59IOPu2uCGN1g6QrX72SjK4UbTkie9fTHaNGGqXcLvu1bhj1XLZXmricT3z863LuZ8I3DEmv_XT9eF-SW93hcc_vHfaPnpHbVC08GXa9TTZn07l4juByFrwoVjCQrzetNP4BlWiPtg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5VrYS4IN4ECgwShAOxUq_fSBXKUykNqVXaquVi1t51G8mxQ5wIhRN_gb_FP-DKL2HWryhUyq2HSEn82F3t7Mw3uzPfEPLaEoZwNOYrocFNRQ8YUxzuUIVqgdBDBNhWVmPp08gcnOofz43zLfK7zIWRYZWlTswUNU8CuUfe1NCwIRZGr7sZFmERbrf_YfpNkRWk5ElrWU6DFWUW-H5GN1YkeRyK5Xd059L9gy7O_RtK-72TzkApKg4ogaFqc8Vi6A1xIQIWhHucCt1nwqQ6GtEQ5VzXhNjzDeGzwHeo5L4LEECYoW0FKg3RcEoSBDQHOxZafXQEd9q9kXtcnWlQx8jBuEoVdBqsIoUnS-RDL86UmdI6ftB-KPa6mbyGfa-HcFbnuP9xnmZ2sn-X3CkALrRyibxHtkR8n9TdnCF72YCTVcJX2oA6uCvu7OUD8idnU04hCeFoJt8z_PL35y80cM0z9Bgi7MVkjP1MESJDEoOL4H_CoD1OJjLOaIavbMuiFzAYT6doplHZRXCWaeAGsJhDJw-XSuL3cCzSRZQ3RbGNC5xA-IyDiwT-wgXQABltg9-HzBdRQ_Y0FUDhRK5ZwDZa7lFPhw6byap_KcgtbcgIo6EV_bgS44mYvU2hmx-BPSSnNyILj8h2nMTiCQGOilLzfUfuOevCMG1EeWqgaZxzgwvOakQtJ9sLCmp2WSEk8ipS6UxAPBQQLxMQz66Rd9Uz05yYZOPdu6UMeYWSSr3VkqqRV9VlVC_yzIjFIlnIeywE6Qjy9Rp5nItc1ZyWnVFb-LS9JozVDZK6fP1KPL7KKMwR5duOamk10ijldtWvTcOo57K91sTlYurhX5cLLxWepkmq7aebx_uS3ELl4Q0PRofPyG2arTsZgb1LtuezhXiOOHPuvygWMJCvN60z_gF3C5P6 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+Oral+ALZ-801%2FValiltramiprosate+on+Plasma+Biomarkers%2C+Brain+Hippocampal+Volume%2C+and+Cognition%3A+Results+of+2-Year+Single-Arm%2C+Open-Label%2C+Phase+2+Trial+in+APOE4+Carriers+with+Early+Alzheimer%27s+Disease&rft.jtitle=Drugs+%28New+York%2C+N.Y.%29&rft.au=Hey%2C+John+A.&rft.au=Abushakra%2C+Susan&rft.au=Blennow%2C+Kaj&rft.au=Reiman%2C+Eric+M.&rft.date=2024-07-01&rft.issn=0012-6667&rft.volume=84&rft.spage=811&rft_id=info:doi/10.1007%2Fs40265-024-02067-8&rft.externalDocID=oai_gup_ub_gu_se_339593 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-6667&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-6667&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-6667&client=summon |